EAM Investors LLC lessened its stake in Codexis, Inc. (NASDAQ:CDXS) by 7.1% during the 3rd quarter, HoldingsChannel reports. The institutional investor owned 145,099 shares of the biotechnology company’s stock after selling 11,126 shares during the quarter. EAM Investors LLC’s holdings in Codexis were worth $2,488,000 at the end of the most recent reporting period.

Other hedge funds also recently added to or reduced their stakes in the company. Rhumbline Advisers lifted its holdings in shares of Codexis by 29.1% in the second quarter. Rhumbline Advisers now owns 48,661 shares of the biotechnology company’s stock worth $701,000 after buying an additional 10,983 shares in the last quarter. Bank of New York Mellon Corp lifted its holdings in shares of Codexis by 17.3% in the second quarter. Bank of New York Mellon Corp now owns 204,032 shares of the biotechnology company’s stock worth $2,939,000 after buying an additional 30,124 shares in the last quarter. Metropolitan Life Insurance Co. NY lifted its holdings in shares of Codexis by 25.3% in the second quarter. Metropolitan Life Insurance Co. NY now owns 17,210 shares of the biotechnology company’s stock worth $248,000 after buying an additional 3,475 shares in the last quarter. Castleark Management LLC purchased a new position in shares of Codexis in the second quarter worth $6,239,000. Finally, Victory Capital Management Inc. purchased a new position in shares of Codexis in the second quarter worth $1,440,000. 78.28% of the stock is currently owned by hedge funds and other institutional investors.

In other news, SVP James Lalonde sold 13,453 shares of the stock in a transaction on Tuesday, November 13th. The shares were sold at an average price of $15.40, for a total value of $207,176.20. Following the sale, the senior vice president now owns 158,043 shares of the company’s stock, valued at $2,433,862.20. The sale was disclosed in a legal filing with the SEC, which is available at this hyperlink. Also, Director Thomas R. Baruch sold 25,000 shares of the stock in a transaction on Thursday, September 27th. The shares were sold at an average price of $18.54, for a total transaction of $463,500.00. Following the completion of the sale, the director now directly owns 140,593 shares in the company, valued at approximately $2,606,594.22. The disclosure for this sale can be found here. In the last ninety days, insiders have sold 320,114 shares of company stock worth $5,607,436. 11.40% of the stock is owned by insiders.

A number of equities research analysts recently issued reports on CDXS shares. HC Wainwright set a $17.00 price target on shares of Codexis and gave the company a “buy” rating in a research note on Monday, November 12th. BidaskClub raised shares of Codexis from a “hold” rating to a “buy” rating in a research note on Friday, November 2nd. Zacks Investment Research downgraded shares of Codexis from a “strong-buy” rating to a “hold” rating in a research note on Monday, October 15th. Finally, Craig Hallum upped their price target on shares of Codexis from $15.00 to $20.00 and gave the company a “buy” rating in a research note on Wednesday, September 5th. One equities research analyst has rated the stock with a hold rating, five have assigned a buy rating and one has assigned a strong buy rating to the company’s stock. The stock has a consensus rating of “Buy” and an average price target of $17.40.

Codexis stock opened at $16.90 on Wednesday. Codexis, Inc. has a 52-week low of $5.85 and a 52-week high of $19.60.

Codexis (NASDAQ:CDXS) last released its quarterly earnings results on Thursday, November 8th. The biotechnology company reported ($0.04) earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of ($0.07) by $0.03. The company had revenue of $16.95 million for the quarter, compared to the consensus estimate of $14.63 million. Codexis had a negative net margin of 14.26% and a negative return on equity of 25.72%. Research analysts forecast that Codexis, Inc. will post -0.23 earnings per share for the current year.

TRADEMARK VIOLATION WARNING: “Codexis, Inc. (CDXS) Shares Sold by EAM Investors LLC” was originally posted by Daily Political and is owned by of Daily Political. If you are viewing this story on another publication, it was stolen and republished in violation of U.S. & international trademark and copyright law. The correct version of this story can be viewed at https://www.dailypolitical.com/2018/11/21/codexis-inc-cdxs-shares-sold-by-eam-investors-llc.html.

About Codexis

Codexis, Inc discovers, develops, and sells protein catalysts. It also offers intermediate chemicals products that are used for further chemical processing; and Codex biocatalyst panels and kits that enable customers to perform chemistry screening. The company also provides protein catalyst screening and protein engineering services.

Featured Story: What is a stock buyback?

Want to see what other hedge funds are holding CDXS? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Codexis, Inc. (NASDAQ:CDXS).

Institutional Ownership by Quarter for Codexis (NASDAQ:CDXS)

Receive News & Ratings for Codexis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Codexis and related companies with MarketBeat.com's FREE daily email newsletter.